BUFFALO, NY - August 15, 2025 – A new research paper was published in Volume 16 of Oncotarget on August 13, 2025, titled “Clinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay.”

Global guideline establishes new standard for investigating bioactive lipids related to inflammation, immunity, cancer, and neurodegenerative and cardiovascular diseases. Accurately quantifying them in biological samples is challenging and requires rigorous methodologies.

A research team led by Dr. Juyeon Jung at the Bio-Nano Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), has developed a nanobody-based technology that can precisely identify and attack only lung cancer cells, opening new possibilities for cancer therapy.

A new study has identified a set of plasma proteins that can predict whether patients with triple-negative breast cancer (TNBC) will respond to immunotherapy. 

Far from being mere cellular building blocks, amino acids have emerged as powerful regulators of cancer growth and immune function.

Researchers at Columbia Engineering have built a cancer therapy that makes bacteria and viruses work as a team. In a study published today in Nature Biomedical Engineering, the Synthetic Biological Systems Lab shows how their system hides a virus inside a tumor-seeking bacterium, smuggles it past the immune system, and unleashes it inside cancerous tumors. 

A new review reveals how lactate and its derivative lactylation process drive breast cancer progression, opening new therapeutic possibilities.

A landmark mini-review from Peking Union Medical College Hospital delivers a snapshot of nine PD-1/IL-2 bi-functional drugs now in clinical trials. By silencing PD-1 and selectively fueling T cells with refined IL-2 in one molecule, these agents reinvigorate exhausted immune soldiers while sparing healthy tissue, promising safer and broader cancer cures.

Researchers from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), have made a significant advancement that could reshape the treatment landscape for hepatocellular carcinoma (HCC), the most common type of liver cancer, which often resists treatment and recurs. This cancer is especially prevalent in Southeast Asia and China. The research, published in the journal Science Translational Medicine, revealed a previously unknown mechanism that allows HCC to grow more aggressively and evade existing therapies. The team also developed a new small molecule inhibitor that could improve treatment options for HCC patients.

Transplanted organs are more likely to be rejected by the immune system when there is a mismatch between donor and recipient human leukocyte antigens (HLA). A Medical University of South Carolina team reports in Frontiers in Immunology that it has fitted regulatory T-cells, whose job is to suppress immune responses, with an artificial receptor and other genetic machinery that enable them to target and neutralize B-cells producing antibodies against the mismatched HLA.